Business Wire

Seoul Semiconductor First in the World to Receive Low Risk Eye Safety Certification for its Natural Light LED SunLike


The world-leading LED company Seoul Semiconductor (Head office: Ansan-si, Korea, CEO: Chung Hoon Lee, hereinafter Seoul Semiconductor) announced that SunLike, which implements light which comes closest to sunlight, received an RG-1 Eye Safety certification based on the safety of its light source and was recognized for the highest level of safety amongst 25W COB type LED.

This press release features multimedia. View the full release here:

25W SunLike light source which acquired RG-1 grade in Eye Safety certification (Photo: Business Wire ...

25W SunLike light source which acquired RG-1 grade in Eye Safety certification (Photo: Business Wire)

Eye Safety certification is a rating based on safety from analyzing the LED wavelengths. In Europe, where top priority is placed on the safety of lighting, Eye Safety certification is essential and the light source must be higher than RG-3 level, otherwise eye sight may be impaired if stared at directly and there has to be a warning label on the finished product.

SunLike received the RG-1 grade in Eye Safety certification with its natural light LED which applies TRI-R technology from Toshiba Materials (Head office: Yokohama city, Kanagawa Prefecture, CEO: Aoki Kokumei). The RG-1 grade is granted to a safe light source for which there is no biological risk, even if our entire lives were spend exposed to the light source. Particularly, the acquisition of the RG-1 grade for the first time for a 25 W single light source widely used for commercial and residential lighting is highly significant, as a natural light source with the highest level of safety has been commercialized.

The interest in the impact of light on health has increased tremendously with the award of the Nobel Prize in Physiology or Medicine to professor Jeffrey C. Hall from Maine University, professor Michel Rosbash from Brandeis University and professor Michael Young from Rockefeller University of USA, acknowledging the causal relationship between biorhythms and human health. So the natural light LED SunLike, which acquired the RG-1 grade in Eye Safety certification, is in the spotlight as a next generation light source.

In addition, SunLike doesn’t have the blurring problem occurring in most other artificial light sources and as a result, the unique color an object has comes out the best and the three-dimensional effect of the object remains intact. Thanks to these features, SunLike is expected to be widely applied, not only in places requiring a healthy lighting environment such as home, offices, schools, medical institutions, etc., but also commercial facilities, museums, clothes stores, distribution stores, etc. which have to reproduce the natural color and texture of the object.

“Interest in the relationship between light and human health is increasing with the award of Nobel Prize in Physiology or Medicine by the scientists researching biorhythms and consequently also the volume of inquiries for SunLike from commercial, industrial and medical institutions, as well as customers in lighting, throughout the world,” according to Dr. Kibum Nam, Head of Seoul’s R&D Center and Chief Technology Officer.

“We are opening the healthy lighting era of natural light thanks to LED SunLike which comes closest to the spectrum of sunlight as human beings have enjoyed for thousands of years.”

* What is TRI-R technology?

TRI-R is a registered trademark of Toshiba Material Co., Ltd. It is a natural light LED light source technology that reproduces the solar spectrum developed by the concept and spectrum technology of natural light.

*What is Eye Safety?

Eye Safety refers to the international standard the International Commission on Illumination adopted as standard (CIE S 009:2002) which defines the standard of LED illumination for the purpose of safety for the eyes and skin. The relevant standard is defined in IEC/EN 62471. Since the luminaire was widely used for LED, the assessment of risks to blue light became integral and the standard of IEC/EN 62471 began to apply to lighting and system using LED from September the 1st, 2009.

[Risk Classification Table]

Risk Group   Risk
No Risk (Exempt) No photobiological- risk
RG 1 (Low Risk) No photobiological risk in normal daily life
RG 2 (Intermediate Risk) Doesn’t cause risk but feels unpleasant due to bright light or heat
RG 3 (High Risk) Dangerous even if a human is exposed to light instantaneously

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

For more information about Seoul Semiconductor, please visit

# Trademarks
Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Contact information

Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49 (0)89 450 3690-0
North America
Seoul Semiconductor Inc.
David Cox
Tel: +1 (919) 410-9856
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements